Aberrant Antigen Expression in Children with Acute Leukemia A Flow Cytometric Analysis

Jahan, Nusrat; Sattar, Humayun; Tarafder, Shirin; Roy, Chandan Kumar; Rahman, Irin; Johora, Fatima Tuj

doi:10.3329/bjmm.v12i1.51685

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall frequency of aberrancy was 38.7% in all AL patients; some patients express more than one aberrant marker, as demonstrated in table [2].…”

Section: Resultsmentioning

confidence: 84%

See 1 more Smart Citation

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Moustafa

Mahfouz

Mohamed

et al. 2023

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: Patients with acute leukemia [AL] may express aberrant antigens that are normally restricted to a different lineage. We evaluated the frequency of aberrancy in AL patients.Aim of the work: Evaluation and analysis of the incidence of aberrant phenotypes in mononuclear cells in AL patients and their relation to hematological parameters. Patients and Methods: This observational descriptive study was conducted on 150 newly diagnosed cases of AL over the period from August 2017 to March 2021. Flow cytometry was performed by Becton Dickinson [BD] FACS Calibur/BD FACS Canto flow cytometers using monoclonal antibodies against cell markers. Results: The overall frequency of aberrancy was 38.7% [58/150] in all AL patients. Aberrant antigenic expression was more frequent in acute lymphoblastic leukemia [ALL] than acute myeloid leukemia [AML], T-ALL with aberrant expression was 66.6% of all T-ALL patients, while B-ALL with aberrant expression was 45.8% of all B-ALL patients, and AML with aberrant expression was 31.1% of all AML patients. Conclusion: Aberrant phenotypes were found with considerable frequency in AL patients, and the implication of aberrant markers can help in disease monitoring, detecting measurable residual disease, and determining risk stratification and treatment intensity.

show abstract

“…The overall frequency of aberrancy was 38.7% in all AL patients; some patients express more than one aberrant marker, as demonstrated in table [2].…”

Section: Resultsmentioning

confidence: 84%

“…In several cases of AL, blasts of one lineage do not exhibit the markers of normal differentiation but express unusual markers in which myeloidassociated antigens are expressed in lymphoblasts and lymphoid-associated antigens are expressed in myeloblasts. This phenomenon is called aberrant phenotypes [2] .…”

Section: Introductionmentioning

confidence: 99%

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Moustafa

Mahfouz

Mohamed

et al. 2023

International Journal of Medical Arts

View full text Add to dashboard Cite

show abstract

“…Acute leukemia is a term used to define the malignant transformation that affects the stem cell precursors of the myeloid lineage (red blood cells, while blood cells and platelets) and/or the lymphoid lineage (B and T lymphoid cells) which evolves rapidly due to the underlying genetic aberrations that induce the neoplastic alterations and clonal proliferation. [1][2][3] In order to accurately diagnose and classify AL, integrative multiple steps are crucial to be done which are clinical history and examination, morphological, cytochemical, immunophenotypic and cytogenetic and molecular analysis. The immunophenotyping by multi parametric FCM of the immature malignant blast population of AL is vital to determine the lineage of the blast cell and hence to classify AL.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of aberrant expression of CD markers in acute leukemia cells

kareem Shwani,

Sadiq Muhammad,

Hassan Hamza

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Worldwide immunophenotyping by flow cytometry (FCM) in acute leukemia (AL) is the golden step in the diagnosis. It’s very common for acute leukemias to aberrantly express antigens or cluster of differentiation (CD) markers which are usually expressed in other lineages of the disease hence this study aimed at determining the prevalence of aberrancy in AL and to find out the frequency of each aberrant CD marker and their association with the clinic-hematological profile of the cases. Methods: Following history and clinical examination of enrolled patients, blood and/or bone marrow aspirate was drawn for morphological examination and immunophenotyping by FCM from 86 newly diagnosed acute leukemia cases then multiple steps procedure was applied followed by interpretation of the results. Results: The prevalence of aberrant phenotype was 46.5%. The proportional frequency of aberrant phenotype in acute myeloid leukemia (AML) was 41%, in B-acute lymphoblastic leukemia (B-ALL) was 48.8% and in T-acute lymphoblastic leukemia (T-ALL) was 66.6%. The commonest aberrant CD markers in AML were CD22 and CD2, in B-ALL were CD66c and CD13 while in T-ALL were CD13 and CD33. The aberrant phenotype harbored lower white blood cell (WBC) count and blast percentage in PB, also splenomegaly was more frequent in lymphoid positive (Ly+) AML and myeloid positive (My+) T-ALL while in B-ALL, splenomegaly was more frequent in myeloid negative (My-) B-ALL. Conclusion: Aberrant phenotype prevalence in our study sample was comparable to other studies, considerable frequency of aberrant markers is present in cases of AL and some variations exist regarding the clinical and hematological profile of the aberrant group.

show abstract

Aberrant Antigen Expression in Children with Acute Leukemia A Flow Cytometric Analysis

Cited by 2 publications

References 11 publications

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Evaluation of aberrant expression of CD markers in acute leukemia cells

Contact Info

Product

Resources

About